507480-08-2

Upstream product

• 507480-25-3 (3R,4S)-3-(4-Methoxy-benzyloxy)-4-methyl-hept-6-ynal 
• 1730-25-2 allylmagnesium bromide 
• 507480-23-1 Toluene-4-sulfonic acid (S)-2-[(2R,4R)-2-(4-methoxy-phenyl)-[1,3]dioxan-4-yl]-propyl ester 
• 507480-07-1 (3R,4S)-3-(4-Methoxy-benzyloxy)-4-methyl-hept-6-yn-1-ol 
• 507480-06-0 (2R,4R)-2-(4-Methoxy-phenyl)-4-((S)-1-methyl-but-3-ynyl)-[1,3]dioxane 
• 507480-05-9 (2S)-2-[(4R)-2-(4-methoxyphenyl)-1,3-dioxan-4-yl]propan-1-ol 
• 507480-04-8 (2R,4R)-2-(4-methoxyphenyl)-4-((S)-1-methyl-prop-2-enyl)-[1,3]dioxane 

Downstream Products

• 507480-26-4 (4R,6R)-4-allyl-2-(4-methoxyphenyl)-6-[(1S)-1-methylbut-3-ynyl]-1,3-dioxane 
• 507480-28-6 4-Nitro-benzoic acid (1S,3R,4S)-1-allyl-3-(4-methoxy-benzyloxy)-4-methyl-hept-6-ynyl ester 

Relevant academic research and scientific papers

Formal total synthesis of salicylihalamides A and B

An efficient synthesis of the macrolactone 3 of the salicylihalamides in 10 linear steps from alkene 6 is described. The key steps involved a Stille coupling between the chiral stannane 5 and benzyl bromide 4, which produced alkene 15 in good yield, and subsequent base-induced macrolactonization then gave compound 3. Macrolactone 3 was then converted into the known salicylihalamide A intermediate 18 in a three-step sequence. Compound 3 was also converted into another known salicylihalamide A and B intermediate 23 in a five-step sequence.